Copyright
©The Author(s) 2017.
World J Gastroenterol. Apr 21, 2017; 23(15): 2771-2784
Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2771
Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2771
Figure 9 Receiver operating characteristic curves for 3-indoleacetic acid, indoleacetic acid, L-carnitine, and pyroglutamic acid in the non-alcoholic steatohepatitis and non-alcoholic fatty liver disease groups.
NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis.
- Citation: Dong S, Zhan ZY, Cao HY, Wu C, Bian YQ, Li JY, Cheng GH, Liu P, Sun MY. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(15): 2771-2784
- URL: https://www.wjgnet.com/1007-9327/full/v23/i15/2771.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i15.2771